ADHD

NeuroSigma Announces Acceptance into 2024 Cohort of the KidsX Accelerator Program

Retrieved on: 
Donnerstag, Mai 9, 2024
FDA, ASD, Senior, ADHD, Monarch, Zorg, DSM-IV codes, Mental health, Autism spectrum, Nursing

LOS ANGELES, May 09, 2024 (GLOBE NEWSWIRE) -- NeuroSigma, Inc. today announced its acceptance into the 2024 cohort of the KidsX Accelerator Program .

Key Points: 
  • LOS ANGELES, May 09, 2024 (GLOBE NEWSWIRE) -- NeuroSigma, Inc. today announced its acceptance into the 2024 cohort of the KidsX Accelerator Program .
  • NeuroSigma is a Los Angeles-based bioelectronics company focused on external trigeminal nerve stimulation (eTNS) technology for the treatment of neurological and neuropsychiatric disorders.
  • “We are honored to be accepted into the KidsX 2024 accelerator program.
  • The device is a wearable, home-use neurostimulation product, and was accepted into the KidsX Pediatric Mental and Behavioral Health focus area.

Supernus Announces First Quarter 2024 Financial Results

Retrieved on: 
Mittwoch, Mai 8, 2024
FDA, MDD, Phase, Total, Safety, NDA, Food, ADHD, Growth, CNS, Prescription, IQVIA, DSM-IV codes, Attention deficit hyperactivity disorder, Patient, MADRS, Operating cost, Symantec Endpoint Protection, Central nervous system, CRL, AISRS, GAAP, Investigational New Drug, Pharmaceutical industry

ROCKVILLE, Md., May 08, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the first quarter of 2024 and associated Company developments.

Key Points: 
  • ROCKVILLE, Md., May 08, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the first quarter of 2024 and associated Company developments.
  • "We are pleased to announce another strong quarter for Qelbree, which delivered robust growth of 75% in net sales compared to the same quarter in the prior year," said Jack Khattar, President and CEO of Supernus.
  • Total IQVIA prescriptions were 176,503 for first quarter 2024, an increase of 31% compared to the prior year period.
  • See “Non-GAAP Financial Information” section for information on non-GAAP financial measures.

Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Dienstag, Mai 7, 2024
Angioedema, FDA, Mouth, NDA, Food, Swelling, Skin, Research, Attention deficit hyperactivity disorder, Insurance, Trial of the century, ADHD, Lennox–Gastaut syndrome, Dermatology, Seizure, Prescription, Public expenditure, Riluzole, Vomiting, Patent, Patient, Adrenaline, Common stock, Anaphylaxis, Epilepsy, Diazepam, PD, Therapy, Serdexmethylphenidate/dexmethylphenidate, Type, Pharmaceutical industry

“We continue to successfully execute on our growth strategy as demonstrated by our first quarter results,” said Daniel Barber, Chief Executive Officer of Aquestive.

Key Points: 
  • “We continue to successfully execute on our growth strategy as demonstrated by our first quarter results,” said Daniel Barber, Chief Executive Officer of Aquestive.
  • Total revenues increased to $12.1 million in the first quarter 2024 from $11.1 million in the first quarter 2023.
  • Research and development expenses increased to $5.9 million in the first quarter 2024 from $3.5 million in the first quarter 2023.
  • Non-GAAP adjusted EBITDA loss was $7.2 million in the first quarter 2024, compared to non-GAAP adjusted EBITDA loss of $3.9 million in the first quarter 2023.

Foster Counseling and Therapy Announces Specialized Anxiety and OCD Services in Lake in the Hills

Retrieved on: 
Dienstag, Mai 7, 2024
ACT, Grief, LCPC, Social anxiety, OCD, Acceptance, Phobia, ERP, Psychotherapy, Exposure, ADHD, Obsessive–compulsive disorder, GAD, Response, Anxiety, Mental health, Panic, Attention deficit hyperactivity disorder, Judgement, Commitment, Community, Individual, Outline of counseling, Nursing

Foster Counseling and Therapy is proud to announce its specialized services for anxiety and Obsessive-Compulsive Disorder (OCD) in the Lake in the Hills community.

Key Points: 
  • Foster Counseling and Therapy is proud to announce its specialized services for anxiety and Obsessive-Compulsive Disorder (OCD) in the Lake in the Hills community.
  • Recognized for an inclusive and comprehensive approach, the clinic features a team of highly educated and extensively trained specialists in OCD and Anxiety Therapy .
  • The clinic’s tailored services cater to a broad spectrum of anxiety disorders, including generalized anxiety disorder (GAD), social anxiety, panic disorders, phobias, and OCD.
  • Community members seeking help are encouraged to contact Foster Counseling and Therapy to discover how these specialized services can significantly improve their mental health and well-being.

Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Montag, Mai 6, 2024
Shift, Migraine, FDA, Agitation, Research, EMERGE, Webcast, CNS, Prescription, Reboxetine, Privacy, Medicine, BED, Obstructive sleep apnea, Fibromyalgia, Shift work, Deficit spending, Food, Sleep, System, ADHD, SWD, SYMPHONY, NT1, Therapy, Quality of life, Food and Drug Administration, MDD, Narcolepsy Network, Shirin David, Patient, Somnolence, FOCUS, Safety, Depression, CGRP, Binge eating disorder, Medicare, Cataplexy, Central nervous system, Government, DSM-IV codes, Clinical trial, EDS, NDA, NMDA, GPO, Psychiatry, MD, Idiopathic hypersomnia, Smoking, CMAI, Pivotal, Breakthrough therapy, Growth, Pharmaceutical industry

Auvelity net product sales were $53.4 million for the first quarter of 2024, representing 240% year-over-year growth.

Key Points: 
  • Auvelity net product sales were $53.4 million for the first quarter of 2024, representing 240% year-over-year growth.
  • Total cost of revenue was $6.3 million for the first quarter of 2024.
  • Research and development (R&D) expenses were $36.8 million for the first quarter of 2024, compared to $17.8 million for the comparable period in 2023, respectively.
  • Approximately 95,000 prescriptions were written for Auvelity in the first quarter of 2024, representing a 12% sequential increase versus the fourth quarter of 2023.

Arctic Inspiration Prize awards over $3.2 million to 10 teams across Canada's North

Retrieved on: 
Mittwoch, Mai 8, 2024
Knowledge, Education, NWT, Food, Language, Learning, Woman, Yukon Arts Centre, Disability, Dream, Health, Partnership, Conference, ADHD, YT, Student, Employment, Traditional knowledge, First Nations, Culture, Mental health, Support, Arctic Inspiration Prize, AIP, Growth, K-12, Tourism

WHITEHORSE, YT, May 7, 2024 /CNW/ - Ten innovative teams from across Canada's North were awarded a share of over $3.2 million for their groundbreaking by the North and for the North projects.

Key Points: 
  • WHITEHORSE, YT, May 7, 2024 /CNW/ - Ten innovative teams from across Canada's North were awarded a share of over $3.2 million for their groundbreaking by the North and for the North projects.
  • The prizes were awarded during a celebration held tonight in Whitehorse in partnership with the Arctic Indigenous Investment Conference.
  • "For twelve years now, the Arctic Inspiration Prize has been celebrating excellence of and for the North.
  • Once again this year, I am astounded by the incredible innovation and problem-solving that is happening in the North," said Wally Schumann, Chair of the Arctic Inspiration Prize Charitable Trust.

M8 Pharmaceuticals, an Acino company, signs an exclusive licensing agreement with Supernus for Qelbree® (Viloxazine XR) in Latin America

Retrieved on: 
Dienstag, Mai 7, 2024
FDA, Viloxazine, Food, Fenfluramine, Psychiatry, Partnership, ADHD, CNS, Attention deficit hyperactivity disorder, Patient, DSM-IV codes, Central nervous system, Clinical trial, Pharmaceutical industry

Unlike most ADHD medications on the market, this medication is a non-stimulant option.

Key Points: 
  • Unlike most ADHD medications on the market, this medication is a non-stimulant option.
  • A second phase 4 clinical trial in preschool age children with ADHD is planned to commence in January 2024.
  • A third phase 4 clinical trial is studying the impact of Qelbree® on co-morbid mood symptoms prevalent in patients with ADHD.
  • The collaboration will provide prescribers with a new option to improve the ADHD treatment paradigm for millions of patients.

The American private investment fund XY Booster enhances neurodivergent talent

Retrieved on: 
Dienstag, Mai 7, 2024
Stanford University, Neurodiversity, Tourette syndrome, Work, Dyslexia, Workplace, Developmental coordination disorder, ADHD, Dyscalculia, Employment, Environment, Attention deficit hyperactivity disorder, Workforce, Multimedia, XY, Organization, Creative industries

NEW YORK, May 7, 2024 /PRNewswire/ -- Between 15 and 20% of the world's population is neurodivergent, according to Stanford University's Neurodiversity at Work program. This percentage reveals that at least one in every six people has conditions such as dyslexia, attention deficit hyperactivity disorder (ADHD), Tourette syndrome, dyspraxia and dyscalculia or belongs to the autism spectrum.

Key Points: 
  • XY Booster , with offices in New York, San Francisco, Mexico and Barcelona (Spain), has 40% neurodivergent talent in its workforce.
  • NEW YORK, May 7, 2024 /PRNewswire/ -- Between 15 and 20% of the world's population is neurodivergent, according to Stanford University's Neurodiversity at Work program.
  • According to Mark Long, Chief Marketing Officer of the startup XtraordinarY, focused on enhancing neurodivergent talent and backed by the American private investment fund XY Booster , "creating an environment favorable to neurodiversity and investing in it is beneficial for everyone.
  • "By embracing neurodiversity in the team and in its investment practices, XY Booster can unlock new opportunities, improve decision-making processes, and increase its overall effectiveness as a fund.

4 Trends Showing Mental Health is a Continued Challenge for Americans

Retrieved on: 
Montag, Mai 6, 2024
Loneliness, Mental Health Awareness Month, Happiness, Research, Insomnia, ADHD, Depression, Mental health, Psychological abuse, Mental, Telehealth, Patient, Failure, Child, Millennials, Consultant, Morning Consult, Anxiety, Nursing

Mental health challenges continue to affect Americans, with nearly 3 of 4 (73%) U.S. adults reporting struggles with mental health in 2023.

Key Points: 
  • Mental health challenges continue to affect Americans, with nearly 3 of 4 (73%) U.S. adults reporting struggles with mental health in 2023.
  • "Mental health remains a struggle for many Americans," said Dr. Daniel Fick, RedBox Rx 's chief medical officer.
  • In honor of Mental Health Awareness Month, consider these mental health trends identified in the survey:
    1.
  • Younger Generations are More Likely to Report Mental Health Struggles, Worsening Mental Health
    Gen Zers and Millennials are more likely to report having mental health struggles and more likely to say those struggles worsened in the past year.

Neurologists Describe Childhood Absence Epilepsy as 'Underrecognized' but 'Easily Diagnosed and Treated'

Retrieved on: 
Montag, Mai 6, 2024
Education, System, Learning, Parent, ADHD, Human, Neurology, Seizure, Disease, CAE, Caregiver, Multimedia, Diagnosis, Health

WASHINGTON, May 6, 2024 /PRNewswire/ -- The subtlety of childhood absence epilepsy (CAE) seizures, coupled with their close association with learning and mental health difficulties, can delay diagnosis despite CAE being one of the most common pediatric syndromes in the United States, according to a new expert-led clinical proceedings paper from the Clinical Neurological Society of America.

Key Points: 
  • Childhood absence epilepsy seizures are brief staring spells with loss of awareness that cannot be interrupted by voice or touch.
  • CAE may go undiagnosed or misdiagnosed because it can be mistaken for ADHD or be difficult for parents, teachers and other caregivers to recognize.
  • While CAE usually remits within two years of onset or by early adolescence, the impact on children's social and emotional health can be long term.
  • "Expanding awareness among the public of CAE is the first step to earlier diagnosis and treatment.